Moleculin Biotech (NASDAQ:MBRX) Lowered to Hold Rating by Maxim Group

Maxim Group cut shares of Moleculin Biotech (NASDAQ:MBRX) from a buy rating to a hold rating in a research report sent to investors on Wednesday morning, Marketbeat reports.

Separately, StockNews.com initiated coverage on shares of Moleculin Biotech in a report on Sunday. They issued a “sell” rating on the stock.

Moleculin Biotech Trading Down 17.2 %

NASDAQ:MBRX opened at $0.42 on Wednesday. The business’s fifty day moving average is $1.76 and its 200 day moving average is $2.26. Moleculin Biotech has a 52-week low of $0.40 and a 52-week high of $10.35.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.